Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EPS (Weighted Average and Diluted) (2022 - 2025)

Vivos Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.58 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.58 for Q4 2025, down 107.14% from a year ago — trailing twelve months through Dec 2025 was -$2.07 (up 28.87% YoY), and the annual figure for FY2025 was -$2.07, up 6.76%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.58 at Vivos Therapeutics, down from -$0.49 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.28 in Q4 2024 to a low of -$6.4 in Q3 2022.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.6 (2024), against an average of -$1.86.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 1300.0% in 2023, then soared 90.82% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$5.0 in 2022, then skyrocketed by 39.0% to -$3.05 in 2023, then soared by 90.82% to -$0.28 in 2024, then tumbled by 107.14% to -$0.58 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.58, -$0.49, and -$0.55 for Q4 2025, Q3 2025, and Q2 2025 respectively.